Are you at risk of ovarian cancer?

For women with a family history of ovarian, breast, or related cancers, advanced epigenetic blood-based testing may help detect ovarian cancer at earlier stages, potentially improving survival outcomes.  

Doctor review to determine if testing may be suitable for you
Advanced blood-based testing for high-risk individuals

Request an appointment

Most ovarian cancers are diagnosed at an advanced stage.²

Typical later stage diagnosis

Stage III - IV cancer

<30%¹

5-year survival

Early-stage detection

Stage 1 ovarian cancer

~90%¹

5-year survival

*Survival rates vary by individual and are based on published population data.

~70% of ovarian cancers are diagnosed at an advanced stage²

When it comes to ovarian cancer, earlier-stage diagnosis is usually associated with better outcomes than later-stage disease. Early detection can allow for extra review, assessment or treatment options, potentially improving survival outcomes³.

An emerging approach to clinical assessment

Advanced ovarian cancer blood-based testing is supported by clinical research and is designed to detect biological signals associated with ovarian cancer. Validation studies involving over 300 patients, including individuals from high-risk populations, demonstrated 78.2% sensitivity and 94% specificity.⁴

This type if testing may support specialist clinical decision-making for people at increased risk, when used alongside other diagnostic tools.

The limitations of current investigation methods

Ovarian cancer can be difficult to investigate because its symptoms often overlap with other common conditions⁵.

The CA-125 blood test is commonly used, however, it has known limitations, particularly during the early stages of ovarian cancer⁶. Imaging scans such as ultrasound, CT scans or MRI may also be used.

The only way to confirm an ovarian cancer diagnosis is through a biopsy, usually in surgery⁶.